2008
DOI: 10.1038/jhh.2008.82
|View full text |Cite
|
Sign up to set email alerts
|

Prevalence and treatment of hypertensive patients with multiple concomitant cardiovascular risk factors in The Netherlands and Italy

Abstract: The Anglo-Scandinavian Cardiac Outcomes Trial-LipidLowering Arm (ASCOT-LLA) trial demonstrated the benefits of combined antihypertensive/lipid-lowering treatment over antihypertensive treatment alone in hypertensive patients with X3 additional cardiovascular (CV) risk factors. We assessed the prevalence and treatment of patients with hypertension and X3 additional CV risk factors in The Netherlands and Italy in a retrospective cohort study using the This study shows that primary prevention of CVD in hypertensi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2009
2009
2020
2020

Publication Types

Select...
5
1
1

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(3 citation statements)
references
References 33 publications
0
3
0
Order By: Relevance
“…The authors chose to select a similar patient type to those who participated in the ASCOT-LLA trial, which demonstrated that the addition of atorvastatin to an amlodipine-based antihypertensive regimen lead to improved clinical outcomes in this patient type 3,17 . Furthermore as a group, patients at moderate CV risk are likely to have the greatest number of CV events during the next 10 years due to the large number of patients with this risk profile [27][28][29][30] . Therefore, given the high prevalence of this particular patient group, treating these individuals would have a large impact on the total burden of CVD.…”
Section: Discussionmentioning
confidence: 99%
“…The authors chose to select a similar patient type to those who participated in the ASCOT-LLA trial, which demonstrated that the addition of atorvastatin to an amlodipine-based antihypertensive regimen lead to improved clinical outcomes in this patient type 3,17 . Furthermore as a group, patients at moderate CV risk are likely to have the greatest number of CV events during the next 10 years due to the large number of patients with this risk profile [27][28][29][30] . Therefore, given the high prevalence of this particular patient group, treating these individuals would have a large impact on the total burden of CVD.…”
Section: Discussionmentioning
confidence: 99%
“…7 The development of CVD is multifactorial, 8 with the presence of multiple risk factors increasing the probability of an individual experiencing a cardiovascular (CV) event. 8,9 Clustering of risk factors is now the norm, 8,10,11 with an American study, which reviewed data from the 2001 National Health Interview Survey, estimating that only 10% of the adult population had none of the four risk factors considered: smoking, being overweight, physical inactivity and risky drinking. 10 This picture is mirrored in New Zealand, with Maori and Pacific populations being more likely to be affected by the burden of multiple modifiable risk factors.…”
Section: Introductionmentioning
confidence: 99%
“…1 In patients with hypertension, effective and long-term control of blood pressure (BP) to less than 140/90 mm Hg is expected to potentially reduce the incidence of heart failure by more than 50%, myocardial infarction (MI) by 25%, and stroke by nearly 40%. [2][3][4][5] Several clinical trials show that only one-third of the patients achieve their target BP (<140/90 mm Hg, or <130/80 mm Hg if diabetes or chronic kidney disease is concomitantly present) on a single drug alone, and the remaining patients need combinations of more than 2, 3, and sometimes up to 5 drugs. [6][7][8][9] The asymptomatic nature of hypertension, complex treatment regimens, adverse effects, unwillingness to intensify treatment (by either patient or physician), and poor compliance act as compounding factors that lead to failure of adequate BP control.…”
mentioning
confidence: 99%